Immune checkpoint blockade (ICB) therapy provides remarkable clinical gains and has
been very successful in treatment of melanoma. However, only a subset of patients with …

Although clonal neo-antigen burden is associated with improved response to immune
therapy, the functional basis for this remains unclear. Here we study this question in a novel …

Importance Therapies to inhibit programmed cell death 1 and its ligand (anti–PD-1/PD-L1)
provide significant survival benefits in many cancers, but the efficacy of these treatments …

Activating mutations in GNAQ/GNA11, encoding Gαq G proteins, are initiating oncogenic
events in uveal melanoma (UM). However, there are no effective therapies for UM. Using an …

The urea cycle (UC) is the main pathway by which mammals dispose of waste nitrogen. We
find that specific alterations in the expression of most UC enzymes occur in many tumors …

T-cell exhaustion denotes a hypofunctional state of T lymphocytes commonly found in
cancer, but how tumor cells drive T-cell exhaustion remains elusive. Here, we find T-cell …

Nutrient restriction reprograms cellular signaling and metabolic network to shape cancer
phenotype. Lactate dehydrogenase A (LDHA) has a key role in aerobic glycolysis (the …

Anticancer therapies have been limited by the emergence of mutations and other
adaptations. In bacteria, antibiotics activate the SOS response, which mobilizes error-prone …

Precision oncology has made significant advances, mainly by targeting actionable mutations
in cancer driver genes. Aiming to expand treatment opportunities, recent studies have begun …

While synthetic lethality (SL) holds promise in developing effective cancer therapies, SL
candidates found via experimental screens often have limited translational value. Here we …